Genetic pesticides: Monsanto goes ahead with trials

The Monsanto Company will soon notify the Environmental Protection Agency (EPA) that it plans to conduct the first field test of a genetically-engineered microbial pesticide, thereby becoming the first company to break with the convention whereby private corporations have voluntarily sought approval for genetic engineering experiments from the Recombinant DNA Advisory Committee (RAC) of the National Institutes of Health (NIH). It is assumed that Monsanto's decision was influenced by a preliminary legal injunction blocking NIH approval of such field trials without a formal environmental assessment. EPA will allow tests, after 90 days' notice, if it raises no objections to the protocol. Although EPA will not formally call on RAC to examine the protocol, an agency spokesperson said there is "total agreement" between EPA and RAC on what data must be included.     

Data protection: UK bill improved and approved

The Data Protection Bill, which provides individuals the right of access to computerized data about themselves while preventing unauthorized disclosure of information, passed Britain's House of Commons at its third reading and returned to the House of Lords. Among the amendments added to the controversial legislation was one concerning the transfer of medical information to agencies outside the health system. After extensive lobbying by the medical community, the government agreed that a code of practice governing disclosure of medical data recently developed by an interprofessional working group should apply in principle to computerized records.     

Genetic manipulation: British watchdog reconstituted

Britain's Genetic Manipulation Advisory Group (GMAG) is to be replaced by a new body, the Advisory Committee on Genetic Manipulation (ACGM), slated to consist of representatives of employers' and employees' organizations and technical experts. ACGM will address policy issues and will not review individual experiments, as did GMAG. Those doing individual research projects will instead report to the Health and Safety Executive. One of the first issues likely to be addressed by ACGM is the proposed release of genetically-engineered organisms into the environment. Some members of GMAG have pointed out that the new system does not provide for a permanent mechanism for considering ethical problems arising from new recombinant DNA techniques.     

A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC

The proteins encoded by the classical HLA class I and class II genes in the major histocompatibility complex (MHC) are highly polymorphic and are essential in self versus non-self immune recognition. HLA variation is a crucial determinant of transplant rejection and susceptibility to a large number of infectious and autoimmune diseases. Yet identification of causal variants is problematic owing to linkage disequilibrium that extends across multiple HLA and non-HLA genes in the MHC. We therefore set out to characterize the linkage disequilibrium patterns between the highly polymorphic HLA genes and background variation by typing the classical HLA genes and >7,500 common SNPs and deletion-insertion polymorphisms across four population samples. The analysis provides informative tag SNPs that capture much of the common variation in the MHC region and that could be used in disease association studies, and it provides new insight into the evolutionary dynamics and ancestral origins of the HLA loci and their haplotypes.     

DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis

Hypophosphatemia is a genetically heterogeneous disease. Here, we mapped an autosomal recessive form (designated ARHP) to chromosome 4q21 and identified homozygous mutations in DMP1 (dentin matrix protein 1), which encodes a non-collagenous bone matrix protein expressed in osteoblasts and osteocytes. Intact plasma levels of the phosphaturic protein FGF23 were clearly elevated in two of four affected individuals, providing a possible explanation for the phosphaturia and inappropriately normal 1,25(OH)2D levels and suggesting that DMP1 may regulate FGF23 expression.     

Genome-wide association study identifies five loci associated with susceptibility to pancreatic cancer in Chinese populations

Pancreatic cancer has the lowest survival rate among human cancers, and there are no effective markers for its screening and early diagnosis. To identify genetic susceptibility markers for this cancer, we carried out a genome-wide association study on 981 individuals with pancreatic cancer (cases) and 1,991 cancer-free controls of Chinese descent using 666,141 autosomal SNPs. Promising associations were replicated in an additional 2,603 pancreatic cancer cases and 2,877 controls recruited from 25 hospitals in 16 provinces or cities in China. We identified five new susceptibility loci at chromosomes 21q21.3, 5p13.1, 21q22.3, 22q13.32 and 10q26.11 (P = 2.24 × 10(-13) to P = 4.18 × 10(-10)) in addition to 13q22.1 previously reported in populations of European ancestry. These results advance our understanding of the development of pancreatic cancer and highlight potential targets for the prevention or treatment of this cancer.     

Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease

More than 1,000 susceptibility loci have been identified through genome-wide association studies (GWAS) of common variants; however, the specific genes and full allelic spectrum of causal variants underlying these findings have not yet been defined. Here we used pooled next-generation sequencing to study 56 genes from regions associated with Crohn's disease in 350 cases and 350 controls. Through follow-up genotyping of 70 rare and low-frequency protein-altering variants in nine independent case-control series (16,054 Crohn's disease cases, 12,153 ulcerative colitis cases and 17,575 healthy controls), we identified four additional independent risk factors in NOD2, two additional protective variants in IL23R, a highly significant association with a protective splice variant in CARD9 (P < 1 × 10(-16), odds ratio ≈ 0.29) and additional associations with coding variants in IL18RAP, CUL2, C1orf106, PTPN22 and MUC19. We extend the results of successful GWAS by identifying new, rare and probably functional variants that could aid functional experiments and predictive models.     

Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis

Following up on recent genome-wide association studies (GWAS) of Crohn's disease, we investigated 50 previously reported susceptibility loci in a German sample of individuals with Crohn's disease (n = 1,850) or ulcerative colitis (n = 1,103) and healthy controls (n = 1,817). Among these loci, we identified variants in 3p21.31, NKX2-3 and CCNY as susceptibility factors for both diseases, whereas variants in PTPN2, HERC2 and STAT3 were associated only with ulcerative colitis in our sample collection.